How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?

Vaccine

Volumn 31, Issue 52, 2013, Pages 6201-6209

  Thomas, Roger E ^a   Spragins, Wendy ^b   Lorenzetti, Diane L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Independent Research Consultants   (Canada)

Author keywords

Brighton Collaboration criteria; Serious adverse events; Systematic review; Yellow fever vaccine

Indexed keywords

IMMUNOGLOBULIN M; YELLOW FEVER VACCINE;

ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; ASEPTIC MENINGITIS; BRIGHTON COLLABORATION CRITERIA; CEREBROSPINAL FLUID LEVEL; CRANIAL NEUROPATHY; DATA BASE; DEMYELINATING DISEASE; DISEASE CLASSIFICATION; HEART DISEASE; HERPES ZOSTER; HUMAN; HYPOTENSION; ICD-9; IMMUNOGLOBULIN BLOOD LEVEL; LUNG DISEASE; MENTAL HEALTH; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEIZURE; SYSTEMATIC REVIEW; VISCERA; VISCEROTROPIC DISEASE; YELLOW FEVER;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84888433579     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.050     Document Type: Article

References (109)

1. Monath T.P., Gershman M., Staples J.E., Barrett A.D.T. Yellow fever vaccine. Vaccines 2013, Elsevier/Saunders, Edinburgh, [chapter 38]. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offitt (Eds.).
2. WHO. Yellow fever reported cases. [accessed 09.08.12]. http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tsincidenceyfe.htm.
3. Jentes E.S., Poumerol G., Gershman M.D., Hill D.R., Lemarchand J., Lewis R.F., et al. The revised global yellow fever risk map and recommendations for vaccination 2010 consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 2011, 11:622-632.
4. Hill D.R. Mapping the risk of yellow fever infection. Curr Infect Dis Rep 2012, 14:246-255.
5. Lee L.A., Franzel L., Atwell J., Datta D., Friberg I.K., Goldie S.J., et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. Vaccine 2013, 31S:B61-B72.
6. Monath T.P., Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002, 34:1369-1378.
7. World Health Organization Regional Office for the Western Pacific Region. Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization 2013, WHO Press, Manila, Philippines. 2nd ed.
8. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009, 27:2289-2297.
9. Ruggeberg J.U., Gold M.S., Bayas J.-M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5675-5684.
10. Gold M.S., Gidudu J., Erlewyn-Lajeunesse M., Law B. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 2010, 28:4487-4498. Brighton Collaboration Working Group on Anaphylaxis.
11. Sejvar J.J., Kohl K.S., Bilynsky R., Blumberg D., Cvetkovich J., Galama J., et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5771-5792.
12. Sejvar J.J., Kohl K.S., Gidudu J., Amato A., Bakshi N., Baxter R., et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29:599-612.
13. Gershman M.D., Staples J.E., Bentsi-Enchill A.D., Breugelmans J.G., Brito G.S., Camacho L.A.B., et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012, 30:5038-5058.
14. Whittembury A., Ramirez G., Hernández H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27:5974-5981.
15. Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(6):e1000097. 10.1371/journal.pmed1000097.
16. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Tyler Williamson T. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review. Curr Drug Saf 2011, 6(3):145-154.
17. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 2011, 29(28):4544-4555.
18. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women HIV+ individuals, and older persons: systematic review. J Trop Med Hyg 2012, 86(2):359-372. 10.4269/ajtmh.2012.11-0525.
19. Kelso J.M., Mootrey G.T., Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999, 103:698-701.
20. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26:6077-6082.
21. Breugelmans J.G., Lewis R.F., Agbenu E., Veit O., Jackson D., Domingo C., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31:1819-1829.
22. Fournier J.-P., Bernardin G., Laffont C., Ferrari E., Bernard E., Politano S., et al. Vaccination anti amarile compliquée d'une primo infection grave par le virus de l'immunodeficience humaine (VIH 1): à propos d'une observation. Rétrovirus la Revue du Sida 1989, 2(4):154-156.
23. Silva M.L., Espírito-Santo L.R., Martins M.A., Silveira-Lemos D., Peruhype-Magalhães V., Caminha R.C., et al. Clinical and immunological insights on severe adverse neurotropic/viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 2009, 10.1128/CVI.00369-379.
24. A Joint Statement of the US Public Health Service, North Carolina State Board of Health, Forsyth County Health Department and Bowman Gray School of Medicine. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 1966, 198(6):671-672.
25. Couto A.M., Salomão M.R., Schermann M.T., Mohrdieck R., Suzuki A., Carvalho S.M.D., et al. Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR Morb Mortal Wkly Rep 2010, 59(5):30-32.
26. de, Castro Freire L. Meningo-encefalite post vacinação contra a febre amarilla. Rev Port Pediatr Pueric 1955, 18(2):65-71.
27. Louis J.-J., Chopard Ph, Larbre F. Un cas d'encephalite après vaccination anti-amarile par la souche 17 D. Pédiatrie 1981, XXXVI(7):547-550.
28. Schoub B.D., Dommann C.J., Johnson S., Downie C., Patel P.L. Encephalitis in a 13 year-old boy following 17D yellow fever vaccine. J Infect 1990, 21:105-106.
29. Smith J.H. Encephalitis in an infant after vaccination with 17 D yellow fever virus. Br Med J 1954, 2(4892):852.
30. Thomson W.O. Encephalitis in infants following vaccination with 17 D yellow fever virus: report of a further case. Br Med J 1955, 2(4932):182.
31. Drouet A., Chagnon A., Valance J., Carli P., Muzellec Y., Paris J.F. Méningo-encéphalite après vaccination anti-amarile par la souche 17 D: deux observations. Rev Med Interne 1993, 14(4):257-259.
32. Guimard T., Minjolle S., Polard E., Fily F., Zeller H., Michelet C., et al. Short report: incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med 2009, 81(6):1141-1143.
33. Kengsakul K., Sathirapongsasuti K., Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thailand 2002, 85(1):131-134.
34. Levy S., Mullane K., Miller M., Siva S., Barnes D., Dhaliwal P., et al. Adverse events associated with 17D-derived yellow fever vaccination - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002, 51(44):989-993.
35. McMahon A.W., Eidex R.B., Marfin A.A., Russell M., Sejvar J.J., Markoff L., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007, 25:1727-1734.
36. Merlo C., Steffen R., Landis T., Tsai T., Karabatsos N. Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. Vaccine 1993, 11(6):691.
37. Mounier G., Chabrier S., Bergeron I., Guy C., Ollagnier M. Acute transverse myelitis (ATM) following yellow fever vaccination. Federation of European Pharmacological Societies EPHAR Congress, Abstract 7P071 2001, 23.
38. Fox J.P., Lennette E.H., Manso C., Souza Aguiar J.C. Encephalitis in man following vaccination with 17D yellow fever virus. Am J Hyg 1942, 36(2):117-142.
39. Panthier R. À propos de quelques cas de réactions nerveuses tardives observées chez des nourissons après vaccination antiamarile. Bull Soc Pathol Exot 1956, 49(3):477-494.
40. Chaves M., Riccio P., Patrucco L., Rojas J.I., Cristiano E. Longitudinal myelitis associated with yellow fever vaccination. J Neurovirol 2009, 15:348-350.
41. Miravalle A., Biller J., Silva E., Conneely M., O'Keefe P. Acute disseminated encephalomyelitis following yellow fever vaccination. Arq Neuropsiquiatr 2009, 67(3-A):710-711.
42. Vital C., Vital A., Gbikpi-Benissan G., Longy-Boursier M., Climas M.-T., Castaing Y., et al. Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases. J Peripher Nerv Syst 2002, 7:163-167.
43. Voigt U., Baum U., Behrendt W., Hegemann S., Terborg C., Strobel J. Optikusneuritis nach Impfung gegen Hepatitis A, B und Gelbfieber mit irreversiblem Visusverlust. Klin Monatsbl Augenheilkd 2001, 218:688-690.
44. Feitel M., Watson E.H., Cochran K.W. Encephalitis after yellow fever vaccination. Pediatrics 1960, 25:956-958.
45. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004, 22:2103-2105.
46. Stuart G. Reactions following vaccination against yellow fever. Yellow fever vaccination (World Health Organization monograph series no. 30) 1956, 143-189. Palais des Nations, Geneva.
47. Bae H.-G., Domingo C., Tenorio A., de Ory F., Muñoz J., Weber P., et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008, 197:1577-1584.
48. Belsher J.L., Gay P., Brinton M., DellaValla J., Ridenour R., Lanciotti R., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25:8480-8485.
49. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358(9276):121-122.
50. Douce R.W., Freire D., Tello B., Vasquez G.A. Case report: a case of yellow fever vaccine-associated viscerotropic disease in Ecuador. Am J Trop Med Hyg 2010, 82(4):740-742.
51. Martin M., Tsai T.F., Cropp B., Chang G.-J.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358:98-104.
52. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines 2008, Saunders/Elsevier, Philadelphia, Chapter 36. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
53. Muñoz J., Vilella A., Domingo C., Nicolas J.M., de Ory D., Corachan M., et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med 2008, 15:202-205.
54. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G.L., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004, 132:939-946.
55. Vasconcelos P.F.C., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L.R.S., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358:91-97.
56. Gerasimon G., Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 2005, 98(6):653-656.
57. Kennedy C.C., Mullon J. Yellow fever vaccine associated viscerotropic disease in a young woman: a rare complication of a common vaccine. Crit Care Med 2007, 35(12 Suppl.):A286.
58. Monath T.P. Short report: suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg 2010, 82(5):919-921.
59. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES. J Infect Dis 2008, 198:500-507.
60. Vellozzi C., Mitchell T., Miller E., Casey C.G., Barwick Eidex R., Hayes E.B. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteriod therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg 2006, 75(2):333-336.
61. de Mello Vieira J., Sinari V., Vasconcelos Dias F.V. Um caso de hepatite letal após vacinação anti-amarílica. J Soc Cienc Med Lisb 1965, 129:51-72.
62. Zhou Q. Adverse effects of attenuated yellow fever vaccine with multiple organ injury - a case report. Zhong Hua Yi Xue Za Zhi 2005, 85(13):936.
63. Engel A.R., Vasconcelos P.F.C., McArthur M.A., Barrett A.D.T. Characterization of a viscerotropic yellow fever variant from a patient in Brazil. Vaccine 2006, 24:2803-2809.
64. de Filippis A.M.B., Nogueira R.M.R., Jabor A.V., Schatzzmayr H.G., Oliveira J.C., Dinis S.C.M., et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17 DD vaccination during an outbreak of yellow fever in Brazil. Vaccine 2004, 22:1073-1078.
65. Sulzberger M.B., Asher C. Urticarial and erythema multiforme-like eruptions following injections of yellow fever vaccine. U S Nav Med Bull 1942, 40(2):411-414.
66. Becker H., Lieske H. Allergische Reaktion nach Gelbfieberimpfung. Z Tropenmed Parasitol 1957, 8(1-2):4-7.
67. Panthier R., Husson B.A. Vaccin antiamarile 17D et allergie. Bull Soc Pathol Exot 1957, 50(1):23-28.
68. Truitt G.W. Skin reaction to yellow fever vaccine. Air Surg Bull 1945, 2:382.
69. Martins R.de M., de S.Maia M.de L., dos Santos E.M., de S.Cruz R.L., dos Santos P.R.G., Carvalho S.M.D., et al. Yellow fever post-marketing surveillance in Brazil. Proc Vaccinol 2010, 2:178-183.
70. Nordin J., Parker E., Vazquez-Benitez G., Kharbanda E., Naleway A., Marcy S., et al. Safety of the yellow fever vaccine: a retrospective study. J Travel Med 2013, [in press].
71. Beet E.A. Encephalitis after yellow fever vaccination. Br Med J 1955, 1(4907):226-227.
72. Fior A., Motard A., Dussart P., Djoussou F. Thrombotic thrombocytopenic purpura (Moschowitz Syndrome) and death following yellow fever vaccination. Virchows Archiv 2007, 451(2):583. Abstract PP4-287.
73. Haas L. Encephalitis after yellow fever vaccination. Br Med J 1954, 2(4894):992-993.
74. Kuhn S., Twele-Montecinos T., MacDonald J., Webster P., Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. Can Med Assoc J 2011, 183(4):E243-E245.
75. Lachgar T., Soupison T., Roche-Sicot J. Réaction méningée immune-allergique après une vaccination anti-amarile. La Presse Médicale 1994, 23(32):1493.
76. Miller J.R., Orgel H.A., Meltzer E.O. The safety of egg-containing vaccines for egg-allergic patients. J Allergy Clin Immunol 1983, 71(6):568-573.
77. Nguyen N., Cargino P., Rodor E., Galland M.C., Prost N., Canioni D., et al. Safety of travelers' vaccines: a case of rhabdomyolysis. Abstracts of the 6th annual meeting of the French pharmacological society: joint meeting with the pharmacological societies of Brazil and Portugal 2002, 416. Abstract P35.
78. Scott L.G. Encephalitis after yellow fever vaccination. Br Med J 1954, 2(4896):1108.
79. Swift S. Encephalitis after yellow fever vaccination. Br Med J 1955, 2(4940):677.
80. Vizzotti C., Biscayart C., Stecher D., Perez E., Carrega M.A., Morales C., et al. Yellow fever vaccine (YFV) and evetns supposedly attributable to vaccination or immunization (ESAVIs): Argentina's experience. 14th international congress on infectious disease (ICID) 2010, 629. Abstract. 10.1016/j.ijid.2010.02.
81. Werfel U., Popp W. Letter to the editor. Lancet 2001, 358:1909.
82. Ministério do Saúde, Brasil. Boletim de Atualização - Dezembro/2009. Emergências em Saúde Pública de Importância Nacional (ESPIN) de Febre Amarela Silvestre em São Paulo e no Rio Grande do Sul e a Situação Epidemiólogica Atual no Brasil (2008/2009). [accessed 08.07.13]. http://portal.saude.gov.br/.
83. Ministéro da Saúde, Brasil. Subsídios para discussão e redefinição da estratégia de vacinação contra febre amarela no Brasil. 30-31/07/2009. Ministéro da Saúde, Brasil, 2009. [accessed 08.07.13]. http://portal.saude.gov.br/.
84. Fernandes G.C., Camacho L.A.B., Carvalho M.S., Batista M., de Almeida S.M.R. Neurological adverse events temporarily associated to mass vaccination against yellow fever in Juiz de Fora Brazil, 1999-2005. Vaccine 2007, 25:3124-3128.
85. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
86. Schumacher Z., Bourquin C., Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland-1991-2001. Vaccine 2010, 28:4059-4064.
87. Adhiyaman V., Oke A., Cefal C. Effects of yellow fever vaccination. Lancet 2001, 358:1907-1908.
88. Appenzeller S., Faria A.V., Zanardi V.A., Fernandes S.R., Costallat L.T.L., Cendes F. Vascular involvement of the central nervous system and systemic diseases: etiologies and MRI findings. Rheumatol Int 2008, 28:1129-1137.
89. Rowland M., Plackett T.P., Smith R. Yellow fever vaccine-associated viscerotropic disease. Mil Med 2012, 177(4):467-469.
90. Troillet N., Laurencet F. Letter to the editor. Lancet 2001, 358:1908-1909.
91. Turpo G., Ticona M., Uchuya J., Whittembury A., Seligman S.J. Third case of fatal yellow fever vaccine-associated viscerotropic disease in a young Peruvian woman. Am Soc Trop Med Hyg 2010, 87(5 Suppl. 1):383. [conference of the annual meeting of the Am Soc Trop Med Hyg, Atlanta, November 2012, Conf Pub 87(5 Suppl. 1):383].
92. Van Langenberg E.R. Acute necrosis of the liver. An unusual case. Lancet 1944, 243(6286):244-245.
93. Williams S.E., Klein N.P., Halsey N., Dekker C.L., Baxter R.P., Marchant C.D., et al. Overview of the clinical consult case review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. Vaccine 2011, (29):6920-6927.
94. Lawrence G., Menzies R., Burgess M., et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun Dis Intell 2003, 27(3):307-323.
95. Lawrence G., Burgess M., Menzies R., McIntyre P., Wood N., Boyd I., et al. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 2004, 28(2):244-248.
96. Monath T.P., Cetron M.S., McCarthy K., Nichols R., Archambault W.T., Wold L., et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005, 1(5):207-214.
97. Thomas R.E., Lorenzetti D.L., Spragins W. Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review. Am J Pub Health 2013, 103(3):e16-e29.
98. Miyaji K.T., Luiz A.M., Lara A.N., Chaves T.do S.S., Piorelli R.de O., Lopes M.H., et al. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years or more. Hum Vaccin Immunother 2013, 9(2):277-282.
99. Seligman S.J. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis 2011, 17(10):1891-1893.
100. Schmöeller D., Keiserman M.W., Staub H.L., Velho F.P., Grohe M.de F.M. Letter to the editor. Yellow fever vaccination and Kawasaki disease. Pediatr Infect Dis J 2009, 28(11):1037-1038.
101. Bayas J.-M., González-Álvarez R., Guinovart C. Herpes Zoster after yellow fever vaccination. J Travel Med 2007, 14(1):65-66.
102. Farez M.F., Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011, 68(10):1267-1271.
103. Price D., Jefferson T., Demicheli V. Methodological issues arising from systematic reviews of the evidence of safety of vaccines. Vaccine 2004, 22:2080-2084.
104. Jefferson T., Rudin M., Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004, 4:84-90.
105. Geier D.A., Geier M.R. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006, 27(4):401-413.
106. Kouwenaar W. The reaction to yellow fever vaccine (17D), particularly in allergic individuals. Documenta de Medicina Geographica et Tropica 1953, 5(1):75-84.
107. Sprague H.B., Barnard J.H. Egg allergy. Significance in typhus and yellow fever vaccination. Naval Med Bull 1945, 45(1):71-74.
108. Swartz H. Systemic allergic reaction induced by yellow fever vaccine. J Lab Clin Med 1943, 43:1663-1667.
109. Martin M., Weld L.H., Tsai T.F., Mootrey G.T., Chen R.T., Niu M., et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001, 7(6):945-951.